Skip to main content
1313 search results for:

Radioimmunotherapy 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | Lung Cancer | OriginalPaper

    CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer

    Lung cancer is globally recognized as the leading cause of cancer-related death and has the highest mortality rate among cancers [ 1 , 2 ]. The main treatment options for lung cancer include surgical intervention, radiotherapy (RT), chemotherapy …

  2. 08-12-2023 | Radioimmunotherapy | OriginalPaper

    [177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models

    GC is a tumor that exhibits moderate sensitivity to radiation [ 1 ]. Radiation therapy is widely used in cancer treatment to induce DNA damage in actively proliferating malignant cells. Additionally, radiation exposure can increase antigen …

  3. Open Access 01-12-2022 | Radioimmunotherapy | OriginalPaper

    Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer

    According to the latest data released by the International Agency for Research on Cancer, the colorectal cancer is the second leading cause of cancer deaths, accounting for 10% of the total number of cancers diagnosed and cancer-related deaths …

  4. Open Access 01-12-2023 | Glioblastoma | OriginalPaper

    First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study

    Despite continuous efforts in basic science and clinical research, glioblastoma (GBM) is still associated with only poor prognosis. After surgical cytoreduction and standard adjuvant treatment with radiation and chemotherapy, approved maintenance …

  5. Open Access 01-12-2023 | Prostate Cancer | OriginalPaper

    CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

    We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC) …

  6. 01-07-2021 | Radioimmunotherapy

    Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice

    Radioimmunotherapy (RIT) is an effective antitumor strategy for coupling radioisotopes to specific molecules that identifiably and selectively seek the cancer cells, one form of which is selective internal radiotherapy (SIRT), radiation can be …

  7. 01-04-2021 | Radioimmunotherapy

    Potential of three-step pretargeting radioimmunotherapy using biotinylated bevacizumab and succinylated streptavidin in triple-negative breast cancer xenograft

    Radioimmunotherapy (RIT) has already been used for more than a decade in clinical practice and has shown promising results for lymphoma treatment [ 1 , 2 ]. Monoclonal antibody (mAb) is used as a radionuclide carrier in RIT, which enables high …

  8. Open Access 01-05-2021 | Radioimmunotherapy | ReviewPaper

    HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging

    Breast cancer is the second most common cancer worldwide and the most frequent among women with an estimated 2.09 million new cases diagnosed in 2018 (11.6% of all cancers). It is the fourth cause of death from cancer overall and the leading cause …

  9. 01-10-2020 | Prostate Cancer | OriginalPaper

    Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer

    While the majority of prostate cancer patients have localized disease at diagnosis, which can be treated with prostatectomy or radiation therapy, 27–53 % will experience biochemical recurrence [ 1 ]. Treatment for these patients includes …

  10. Open Access 01-05-2020 | Radioimmunotherapy | OriginalPaper

    Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry

    To assess the efficacy of radioimmunotherapy (RIT) with 90yttrium-ibrutinib-tiuxetan (90Y-IT) in mantle cell lymphoma, data from 90 patients registered in the RIT Network with a median follow-up (FU) of 5.5 years after RIT were evaluated. 90Y-IT …

  11. 01-05-2019 | Radioimmunotherapy | OriginalPaper

    Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes

    Embryonal tumor with multilayered rosettes (ETMR), C19MC amplified is a new category of embryonal tumors within the 2016 World Health Organization (WHO) classification of tumors of the central nervous system (CNS). Previously called embryonal tumor …

  12. Open Access 01-08-2019 | Radioimmunotherapy | ReviewPaper

    Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy

    Tumor interstitial pressure is a fundamental feature of cancer biology. Elevation in tumor pressure affects the efficacy of cancer treatment and results in the heterogenous intratumoral distribution of drugs and macromolecules. Monoclonal …

  13. 01-08-2019 | Radioimmunotherapy | Letter

    Central nervous system neuroblastoma metastases pseudoprogression following intraventricular anti-B7-H3 radioimmunotherapy

  14. 01-10-2019 | Radioimmunotherapy | OriginalPaper

    Biodistribution, pharmacokinetics and radioimmunotherapy of 188Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice

    Background Cetuximab is a fully humanized IgG1 subclass monoclonal that binds specifically to the human epidermal growth factor receptor (EGFR). Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many human …

  15. 01-04-2021 | Radioimmunotherapy | OriginalPaper

    IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab—pharmacokinetic modeling to optimize therapeutic index

    Many tumors develop leptomeningeal metastases, where cancer cells invade the meninges of the central nervous system and spread through the cerebrospinal fluid (CSF). There is no standard of care for cure, and in most cases, palliation is possible …

  16. 01-07-2019 | Radioimmunotherapy | OriginalPaper

    Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?

    Radioimmunotherapy was recently introduced as a targeted therapy method, in which radiation from radionuclides is delivered to the tumor more selectively by the use of antibodies directed towards tumor-associated antigens. 131 I-tositumomab …

  17. 01-12-2019 | Glioblastoma | ReviewPaper

    Radioimmunotherapy (RIT) in Brain Tumors

    Annually, the incidence of brain tumors has slightly increased and also the patient prognosis is still disappointing, especially for high-grade neoplasms. So, researchers seek methods to improve therapeutic index as a critical aim of treatment.

  18. 01-08-2019 | Radioimmunotherapy | ReviewPaper

    Time for radioimmunotherapy: an overview to bring improvements in clinical practice

    Harnessing the patient’s own immune system against an established cancer has proven to be a successful strategy. Within the last years, several antibodies blocking critical “checkpoints” that control the activation of T cells, the immune cells …

  19. 01-06-2019 | Glioblastoma | ReviewPaper

    Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments

    There is a distinct need for new and second-line therapies to delay or prevent local tumor regrowth after current standard of care therapy. Intracavitary radioimmunotherapy, in combination with radiotherapy, is discussed in the present review as a …

  20. 01-03-2001 | OriginalPaper

    Radioimmunotherapy

    Potential as a Therapeutic Strategy in Non-Hodgkin’s Lymphoma

    Lymphomas are the fifth most common malignancy in the United States and are increasing in incidence. Despite being among the most responsive malignancies to radiation and chemotherapy, the majority of patients relapse or have progressive disease.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.